Enver Pasha

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

Retrieved on: 
Monday, August 28, 2023
Research, Mental Health, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Psilocybin, Patent, Intellectual property, 1836 U.S. Patent Office fire, DMT, Tryptamine, Depression, Therapy, Anxiety, United States Patent and Trademark Office, IP, Prodrug, DSM-IV codes, Addiction, Anxiety disorder, NCE, Growth, Safety, Pharmaceutical industry, Enver Pasha

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,707,441, titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.
  • This new patent, issued July 25, 2023, provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives.
  • Enveric’s lead product candidate, EB-373, is a new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

Retrieved on: 
Monday, August 21, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, GLP, Depression, Therapy, Anxiety, Ground substance, Addiction, CDMO, Toxicology, Safety, Pharmaceutical industry, Enver Pasha

Enveric will immediately commence remaining GLP studies to provide critical data required to initiate human trials for EB-373.

Key Points: 
  • Enveric will immediately commence remaining GLP studies to provide critical data required to initiate human trials for EB-373.
  • The company expects to complete all remaining preclinical studies required for Human Research Ethics Committee (HREC) submission in Australia before year-end 2023.
  • Enveric and its contract development and manufacturing organization (CDMO) partner worked together to optimize and scale up the manufacturing process for EB-373, successfully producing sub-kilogram amounts of the EB-373 salt form with 99% purity.
  • With the high purity of EB-373 manufactured drug product, Enveric measured no controlled impurities within the analytical limit of quantitation.

Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Retrieved on: 
Monday, May 22, 2023
Other Health, Research, General Health, Pharmaceutical, Mental Health, Clinical Trials, Science, Biotechnology, Neurology, Alternative Medicine, Other Science, Health, Psilocybin, Depression, University, Therapy, Biochemistry, Enver Pasha, Anxiety, Prodrug, DSM-IV codes, Addiction, Manuscript, Pharmaceutical industry

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.
  • A manuscript describing the research has been submitted for peer-reviewed publication and is currently accessible via the following open access platform: https://biorxiv.org/cgi/content/short/2023.05.16.540994v1 .
  • Of these active prodrugs, two distinct molecules were selected to proceed further as potential therapies for anxiety disorders.
  • “To address this issue, we designed a series of novel psilocin prodrug derivatives that are able to release therapeutically relevant levels of the psychoactive agent psilocin, with improved pharmacokinetic concentration and profiles.

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Mental Health, Alternative Medicine, Health, Pharmaceutical, Psilocybin, Patent, Depression, Therapy, Anxiety, United States Patent and Trademark Office, ISR, Patent Cooperation Treaty, IP, PCT, Prodrug, Addiction, Anxiety disorder, NCE, Family, Mental health, Pharmaceutical industry, Enver Pasha

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.
  • The soon-to-issue patent, titled, “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter claims for a family of novel prodrug derivatives of psilocin, including EB-373, Enveric’s lead product candidate.
  • The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.
  • Additionally, Enveric has filed further composition of matter patent applications with the USPTO for psilocin prodrugs, including compositions comprising a crystalline molecular structure.

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, May 15, 2023
Research, Mental Health, Cannabis, Clinical Trials, Biotechnology, Pharmaceutical, Health, Natural Resources, Science, Other Science, Exercise, Depression, Drug development, Therapy, Enver Pasha, Anxiety, Corporate spin-off, Consultant, Addiction, Anxiety disorder, Ako (actress), Pharmaceutical industry, Security (finance), Ákos

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2023 ended March 31, 2023.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2023 ended March 31, 2023.
  • Enveric announced a cost reduction plan to extend its financial runway into the first quarter of 2024.
  • Enveric now plans to engage with strategic advisors to identify and pursue alternative routes to capture value from these assets.
  • As of March 31, 2023, the Company had cash and cash equivalents of $12.56 million and working capital of $10.40 million.

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

Retrieved on: 
Monday, April 3, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Molecule, Acceleration, Depression, Therapy, Addiction, COVID-19, Therapeutic Goods Administration, Social stigma, Mental, CNS, Prodrug, Government, Net, TGA, Treatment, Pharmaceutical industry, Cryptocurrency, Anxiety, Enver Pasha

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2022.
  • “In early 2023, we announced the establishment of our Australia-based subsidiary, Enveric Therapeutics Pty.
  • Ltd, and we are rapidly preparing to initiate the planned Phase 1 trial of EB-373.
  • As of December 31, 2022, the Company had cash and cash equivalents of $17.7 million and working capital of $14.4 million.

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

Retrieved on: 
Tuesday, March 21, 2023
Mental Health, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CTX, Depression, Therapy, Enver Pasha, Anxiety, Clinical trial, Therapeutic Goods Administration, CNS, New chemical entity, Addiction, Investigational New Drug, MD, NCE, CTN, TGA, Research, IND, Research and Development Tax Incentive, Pharmaceutical industry

Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

Key Points: 
  • Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.
  • Enveric’s lead drug candidate, EB-373, is a next-generation synthetic New Chemical Entity (NCE) designed as a psilocin prodrug and developed leveraging its Psybrary™ drug discovery platform.
  • Enveric expects to initiate a Phase 1 first-in-human clinical trial investigating EB-373 targeting anxiety disorders in the fourth quarter of 2023.
  • “Given this, we are eager to initiate our clinical development program of EB-373 in Australia and look forward to benefiting from the country’s high-quality clinical research sites.”

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 28, 2023
Health, Mental Health, Biometrics, Anxiety, Biotechnology, VC, Therapy, Clostridium, Cancer, University, Ernst & Young, Immune system, Family, Depression, Accounting, Clostridioides difficile infection, Carl Berg, BDO USA, LLP, Drug discovery, BS, CNS, CPA, Employment, University of Massachusetts Chan Medical School, RSU, CFO, HR, VSI, Central nervous system disease, Addiction, Pharmaceutical industry, Management, Nursing, Finance, Patient, Enver Pasha, Vedanta

Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies.

Key Points: 
  • Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies.
  • “We are extremely pleased to add Kevin to the leadership team at Enveric Biosciences.
  • “I am excited to join the team at Enveric at such a crucial time for the Company,” said Mr. Coveney.
  • The grant was approved by the board of directors of the Company and will be made as an inducement material to Mr. Coveney entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

Retrieved on: 
Monday, November 28, 2022
Cannabis, Mental Health, Health, Natural Resources, Pharmaceutical, Biotechnology, COVID-19, Addiction, Nature, Annual report, Anxiety, Form S-1, Security (finance), Depression, Therapy, Form, Coronavirus, Pharmaceutical industry, Enver Pasha

Dr. Joseph Tucker, CEO of Enveric Biosciences, said, We are pleased to have confidentially submitted our registration statement for the spin-off, which we believe will unlock the unrealized value of what we are now calling Akos.

Key Points: 
  • Dr. Joseph Tucker, CEO of Enveric Biosciences, said, We are pleased to have confidentially submitted our registration statement for the spin-off, which we believe will unlock the unrealized value of what we are now calling Akos.
  • Upon consummation of the potential spinoff, if completed, Enveric shareholders, as of the record date for the separation, will own a majority of Akos.
  • Akos is expected to be listed on The Nasdaq Capital Market after the completion of the potential spin-off.
  • Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders.

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

Retrieved on: 
Wednesday, July 13, 2022
Mental Health, Research, Clinical Trials, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Other Science, Science, Knowledge, Pharmacology, SEC, Clinical trial, Anxiety, GSK, Security (finance), Biotechnology, U.S. Securities and Exchange Commission, NASDAQ, Program, Leadership, Contract, WCG, IND, Intention, World Intellectual Property Organization, Patient, Drug discovery, Psilocybin, COVID-19, PTSD, Depression, Phrase, IP, Toxicology, Freedom, PCT, Intellectual property, Sanofi, Research and development, File, Forward-looking statement, CDMO, Toxicity, Cros, Translational research, Board, CNS, Innovation, Nature, Drug development, Doctor of Philosophy, Coronavirus, Pharmaceutical industry, MD, Research, Enver Pasha

Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022.
  • Enverics Clinical Team is led by a past Board-certified psychiatrist and clinical trialist Chief Medical Officer, Dr. Bob Dagher, MD.
  • The first half of the year has indeed been busy and productive for the dedicated team here at Enveric.
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines.